Previous 10 | Next 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...
It used to be that healthcare companies released news at the J.P. Morgan Healthcare Conference. In the last few years, the Friday before the conference became a news dump. Now, the whole week before the conference has become a news extravaganza. The conference is starting later in January t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
Shares of Matinas BioPharma (NYSEMKT: MTNB) lost nearly 17% today after Amarin (NASDAQ: AMRN) reported preliminary full-year 2019 operating results and provided a business update. Both companies are developing drugs based on omega-3 fatty acids to treat cardiovascular disorders, although...
Amarin 's (NASDAQ: AMRN) Vascepa is the only fish oil supplement approved by the FDA to treat anything, and sales have been soaring since the company presented evidence that it can prevent heart attacks for millions of high-risk patients. On Tuesday, the company announced preliminary 2019 res...
Amarin (NASDAQ: AMRN ) provides an update of preliminary 2019 results and additional 2020 guidance. More news on: Amarin Corporation plc, Healthcare stocks news, Read more ...
Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales Professionals in Early 2020 Full-Year 2020 Net Total Revenue Guidance Reiterated at $650 to $...
Matinas BioPharma Holdings, Inc.'s (NYSE: MTNB ) stock grew over 200 percent in the past 12 months and is currently trading close to its 52-week high of $2.49. However, there are a few things which may hamper the stock’s upward trajectory. The company is in nuanced competition with Am...
While it's true that from an investing standpoint "slow and steady" wins the race, that doesn't mean you should avoid the many high-growth opportunities on the market right now. As investors look forward to a new year, a number of companies are poised to gain significantly in 2020 and beyond. T...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...